Large pharma to boost CMOs’ biologics business; report
CMOs are set to gain biologics business and capacity in the coming years as large pharma increasingly outsources to cut costs and speed development, according to a report published today.
CMOs are set to gain biologics business and capacity in the coming years as large pharma increasingly outsources to cut costs and speed development, according to a report published today.
Indian API manufacturer Shasun Chemicals and Drugs turned a previous loss into profit for Q4 of this year as it seeks to make a dent in the biosimilar manufacturing sector.